News
3d
MedPage Today on MSNPulmonary Rehabilitation for COPD Pushes ForwardHome-based pulmonary rehabilitation has been slowly gaining momentum for chronic obstructive pulmonary disease (COPD), but ...
6d
Pharmaceutical Technology on MSNSanofi and Regeneron report results from two Phase III trials of COPD treatmentSanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.
Yet thanks to a new hospital-based educational and advocacy initiative for COPD patients, Croswell has been managing well at ...
A Winnipeg woman who was given a life expectancy of six months after cancer metastasized from her lungs to her brain, liver ...
Canadian wildfire smoke has entered the Upper Midwest and poses significant health impacts in the hardest-hit areas.
(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition ...
Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.
People who lost weight in midlife were less likely to experience heart attacks, strokes, cancer, asthma or chronic ...
In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results